The PheWAS also revealed a nominally significant increased risk (OR = 2.3; p = 0.024) and earlier onset (HR = 2.1; p = 0.022) of anemia among 16p11.2 BP2–3 deletion carriers (Figure 3B; Table S4). This evidence concerns the gene IGFBP2 and anemia.